Sepracor/Aventis Agreement Would Aid Estorra Filings Outside The U.S.
This article was originally published in The Pink Sheet Daily
Executive Summary
Under the tentative deal, Sepracor would be allowed to reference Amoban regulatory filings in Estorra marketing applications outside the U.S. The agreement is conditional on the successful completion of the Aventis/Sanofi merger.
You may also be interested in...
Aventis Must Divest Estorra Rights For FTC Green Light On Sanofi Merger
Aventis has 90 days to sell rights to the insomnia agent back to Sepracor or another buyer approved by the Federal Trade Commission. The agency says Estorra would overlap with Sanofi’s Ambien.
Aventis Must Divest Estorra Rights For FTC Green Light On Sanofi Merger
Aventis has 90 days to sell rights to the insomnia agent back to Sepracor or another buyer approved by the Federal Trade Commission. The agency says Estorra would overlap with Sanofi’s Ambien.
Sanofi-Aventis Picks Two To Head U.S.: Rothwell, Soriot On Management Committee
Sanofi's Tim Rothwell will continue to serve as U.S. CEO, while Aventis' Soriot will head U.S. commercial operations. French market regulator extends closing date of merger to July 30, citing extra time needed for FTC review.